Santarpia M - Search Results

1

Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach.

Speranza D, Santarpia M, Luppino F, Omero F, Maiorana E, Cavaleri M, Sapuppo E, Cianci V, Pugliese A, Racanelli V, Camerino GM, Rodolico C, Silvestris N. Speranza D, et al. Among authors: santarpia m. Expert Opin Drug Saf. 2024 Nov;23(11):1405-1418. doi: 10.1080/14740338.2024.2363471. Epub 2024 Jun 3. Expert Opin Drug Saf. 2024. PMID: 38819976 Review.

2

Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity.

Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG; CI-PeriNomS Group. Cavaletti G, et al. J Peripher Nerv Syst. 2019 Mar;24(1):111-119. doi: 10.1111/jns.12306. Epub 2019 Feb 8. J Peripher Nerv Syst. 2019. PMID: 30672664

3

NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma.

Santarpia M, Aliprandi M, Claudia Spagnolo C, Avan A, Rosell R, Andrea Zucali P, Giovannetti E. Santarpia M, et al. Lung Cancer. 2024 Nov 7;198:108024. doi: 10.1016/j.lungcan.2024.108024. Online ahead of print. Lung Cancer. 2024. PMID: 39547104

4

Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System.

Cicala G, Russo G, Santoro V, Franchina T, Silvestris N, Santarpia M, Spina E, Barbieri MA. Cicala G, et al. Among authors: santarpia m. Pharmaceuticals (Basel). 2024 Sep 25;17(10):1266. doi: 10.3390/ph17101266. Pharmaceuticals (Basel). 2024. PMID: 39458907 Free PMC article.

5

Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

Muscolino P, Scimone C, Sapuppo E, Micali V, Vasta I, Santacaterina A, Santarpia M, Russo A. Muscolino P, et al. Among authors: santarpia m. Clin Lung Cancer. 2024 Sep;25(6):e262-e267. doi: 10.1016/j.cllc.2024.06.003. Epub 2024 Jun 10. Clin Lung Cancer. 2024. PMID: 38944565 No abstract available.

6

MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.

Nucera F, Ruggeri P, Spagnolo CC, Santarpia M, Ieni A, Monaco F, Tuccari G, Pioggia G, Gangemi S. Nucera F, et al. Among authors: santarpia m. Int J Mol Sci. 2024 Jun 18;25(12):6685. doi: 10.3390/ijms25126685. Int J Mol Sci. 2024. PMID: 38928392 Free PMC article. Review.

7

Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18.

Zhang Y, Zeng H, Qi C, Tan S, Huang Q, Pu X, Suda K, Santarpia M, Tian P, Li Y. Zhang Y, et al. Among authors: santarpia m. Transl Lung Cancer Res. 2024 Apr 29;13(4):875-884. doi: 10.21037/tlcr-24-113. Epub 2024 Apr 9. Transl Lung Cancer Res. 2024. PMID: 38736500 Free PMC article.

8

Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?

Spagnolo CC, Pepe F, Ciappina G, Nucera F, Ruggeri P, Squeri A, Speranza D, Silvestris N, Malapelle U, Santarpia M. Spagnolo CC, et al. Among authors: santarpia m. Crit Rev Oncol Hematol. 2024 May;197:104332. doi: 10.1016/j.critrevonc.2024.104332. Epub 2024 Apr 4. Crit Rev Oncol Hematol. 2024. PMID: 38580184 Free article. Review.

9

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A, Macerelli M, Polo V, Pilotto S, Santarpia M, Cumerlato E, Da Ros V, Targato G, Bortolami A, Bonanno L, Ferro A, Dal Maso A, Frega S, Guarneri V. Pasello G, et al. Among authors: santarpia m. Oncologist. 2024 Jul 5;29(7):596-608. doi: 10.1093/oncolo/oyae043. Oncologist. 2024. PMID: 38520745 Free PMC article.

10

Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.

Spagnolo CC, Campo I, Campennì A, Cardile D, Cannavò S, Silvestris N, Santarpia M, Ruggeri RM. Spagnolo CC, et al. Among authors: santarpia m. Hormones (Athens). 2024 Dec;23(4):759-764. doi: 10.1007/s42000-024-00535-0. Epub 2024 Feb 29. Hormones (Athens). 2024. PMID: 38421588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters